Souhaitez-vous accéder aux communiqués récents ?

Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.

Se Connecter À Un Compte Lecteur Créer Un Compte Lecteur

06 nov. 2019 16h05 HE | Source: AC Immune SA

AC Immune Hosts Key Opinion Leader Event: ‘Untangling’ Tau Pathology to Treat Alzheimer’s and Neurodegenerative Diseases

Company Provides Key Updates on Tau Pipeline Candidates LAUSANNE, Switzerland, Nov. 06, 2019 (GLOBE NEWSWIRE) -- AC Immune SA (NASDAQ: ACIU), a Swiss-based, clinical-stage biopharmaceutical...
24 oct. 2019 07h00 HE | Source: AC Immune SA

AC Immune to Host Key Opinion Leader Event: ‘Untangling’ Tau Pathology to Treat Alzheimer’s and Neurodegenerative Diseases

LAUSANNE, Switzerland, Oct. 24, 2019 (GLOBE NEWSWIRE) -- AC Immune SA (NASDAQ: ACIU), a Swiss-based, clinical-stage biopharmaceutical company with a broad pipeline focused on neurodegenerative...
20 sept. 2019 07h00 HE | Source: AC Immune SA

AC Immune Receives First Milestone Payment from Lilly in Small Molecule Tau Morphomer™ Program

Lilly to pay CHF30 million development milestone Recognizes progress in ACI-3024 Small Molecule Tau Morphomer™ development LAUSANNE, Switzerland, Sept. 20, 2019 (GLOBE NEWSWIRE) -- AC Immune SA...
17 sept. 2019 02h00 HE | Source: AC Immune SA

AC Immune Receives Milestone Payment in Connection with Initiation of a Phase 2 Trial of Tau PET Tracer PI-2620

Next generation Tau tracer offers potential for earlier and more accurate diagnosis in Alzheimer’s and neurodegenerative diseases The clinical milestone highlights the strength of AC Immune’s Tau...
04 sept. 2019 07h00 HE | Source: AC Immune SA

AC Immune Awarded Michael J. Fox Foundation Grant to Accelerate Development of Parkinson’s Disease Diagnostic Imaging Agent

LAUSANNE, Switzerland, Sept. 04, 2019 (GLOBE NEWSWIRE) -- AC Immune SA (NASDAQ: ACIU), a Swiss-based, clinical-stage biopharmaceutical company with a broad pipeline focused on neurodegenerative...
14 août 2019 07h00 HE | Source: AC Immune SA

AC Immune Reports Q2 2019 Financial Results, Business and Clinical Update

LAUSANNE, Switzerland, Aug. 14, 2019 (GLOBE NEWSWIRE) -- AC Immune SA (NASDAQ: ACIU), a Swiss-based, biopharmaceutical company with a broad clinical-stage pipeline focused on neurodegenerative...
12 août 2019 07h00 HE | Source: AC Immune SA

AC Immune Announces Research Collaboration with University of Pennsylvania Focusing on Pathogenic Protein TDP-43 in Neurodegenerative Diseases

LAUSANNE, Switzerland, Aug. 12, 2019 (GLOBE NEWSWIRE) -- AC Immune SA (NASDAQ: ACIU), a Swiss-based, clinical-stage biopharmaceutical company with a broad pipeline focused on neurodegenerative...
01 août 2019 07h00 HE | Source: AC Immune SA

AC Immune Initiates Ph1b/2a Study of Anti-Phospho-Tau Vaccine in Alzheimer’s Disease

LAUSANNE, Switzerland, Aug. 01, 2019 (GLOBE NEWSWIRE) -- AC Immune SA (NASDAQ: ACIU), a Swiss-based, clinical-stage biopharmaceutical company with a broad pipeline focused on neurodegenerative...
17 juil. 2019 07h00 HE | Source: AC Immune SA

AC Immune Initiates Phase 1 Study of ACI-3024 Small Molecule Tau Morphomer™, an Investigational Treatment for Alzheimer’s Disease

LAUSANNE, Switzerland, July 17, 2019 (GLOBE NEWSWIRE) -- AC Immune SA (NASDAQ: ACIU), a Swiss-based, clinical-stage biopharmaceutical company, today announced dosing of the first subject in a Phase...
11 juil. 2019 08h00 HE | Source: AC Immune SA

AC Immune Hosts KOL Event and Reports Initial Interim Clinical Data for ACI-24 Vaccine to Treat Alzheimer’s Disease-like Symptoms in Subjects with Down Syndrome

Anti-Abeta vaccine demonstrates strong safety and preliminary immunogenicity results in subjects with Down syndromePresentations underscore significant need and opportunity for studying Alzheimer’s...

Page précédente